CD38⁺CD27⁻ on *Mtb*-specific CD4⁺ T cells distinguishes latent from active tuberculosis

Muthya Pragun Acharya^{1*}, Sai Pallavi Pradeep¹, Venkataramappa Srinivasa Murthy²,
Panduranga Chikkannaiah², Vivekanand Kambar³, Satyanarayana Narayanashetty⁴, Sharath
Burugina Nagaraja⁵, Dr Niveditha⁶, Raksha Yoganand⁷ and Vijaya Satchidanandam^{1*}

¹Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru
560012, India

²Department of Pathology, Employees State Insurance Corporation Medical College & Post
Graduate Institute of Medical Sciences & Research (ESIC MC & PGIMSR), Bengaluru
560010, India

³Department of Pulmonology, ESIC MC & PGIMSR, Bengaluru 560010, India

⁴Department of General Medicine, ESIC MC & PGIMSR, Bengaluru 560010, India

⁵Department of Community Medicine, ESIC MC & PGIMSR, Bengaluru 560010, India

⁶Department of Pharmacology, ESIC MC & PGIMSR, Bengaluru 560010, India

⁷Department of Microbiology, ESIC MC & PGIMSR, Bengaluru 560010, India

*Correspondence:

Muthya Pragun Acharya (pragun.m@gmail.com) and Vijaya Satchidanandam
(vijaya@iisc.ac.in)

Keywords: tuberculosis; diagnosis; biomarker; flow cytometry; TNF- α ;

ABSTRACT

RATIONALE. Early and accurate diagnosis followed by timely treatment are the key prerequisites to fight tuberculosis (TB) and reduce its global burden. Despite scientific advances, the rapid and correct diagnosis of both pulmonary and extrapulmonary tuberculosis remains a challenge due to traditional reliance on detection of the elusive bacilli. *Mycobacterium tuberculosis* (*Mtb*)-specific host immune activation and cytokine production has shown significant promise as an alternative means of detecting and distinguishing active disease from latent infection.

OBJECTIVE. Phenotypic characteristics of *Mtb*-specific cytokine-producing immune cell subsets were investigated and queried for their diagnostic ability in identifying active tuberculosis.

METHODS. Subjects belonging to the following groups were recruited – pulmonary, extrapulmonary, latent TB, cured TB, sick controls and healthy controls. Polychromatic flow cytometry was used to identify host immune biomarkers in an exploratory cohort comprising 56 subjects using peripheral blood mononuclear cells. Clinical performance of the identified biomarker was evaluated using whole blood in a blinded validation cohort comprising 165 individuals.

FINDINGS. Frequencies of *Mtb*-specific CD4⁺ T cells of the phenotype CD38⁺CD27⁻ clearly distinguished patients with active tuberculosis from individuals without the disease. CD38⁺CD27⁻CD4⁺ T cells secreting TNF-α upon stimulation with ESAT6/CFP10 peptides had the best diagnostic accuracy at a cut-off of 9.91% [exploratory: 96.67% specificity, 88.46% sensitivity; validation: 96.15% specificity, 90.16% sensitivity]. Additionally, this subset differentiated treatment-naive TB patients from individuals cured of TB following completion of anti-tuberculosis therapy.

INTERPRETATION. *Mtb*-specific CD38⁺CD27⁻TNF- α ⁺CD4⁺ T cell subset is a robust biomarker for TB diagnosis and can determine cure.

IMPACT OF THIS RESEARCH

We identified and validated CD38⁺CD27⁻TNF- α ⁺ as a robust biomarker with diagnostic accuracies >90% in both PBMCs and whole blood that can be translated into a reliable and cost-effective in vitro diagnostic test with ease. By not removing samples with insignificant immune response and instead classifying them as negative, our study represents a truly realistic assessment of the diagnostic accuracy of the identified biomarker in a clinical setting.

INTRODUCTION

Tuberculosis which remains one of the world's deadliest infectious diseases with significant morbidity and mortality affects roughly 10 million people and claims 1.5 million lives annually (1). In India alone, 2.4 million people were affected by TB in 2019 (2). Major hurdles in controlling TB include high number of latently infected individuals (LTBI) (approximately 23% of the world's population, of which 5–15% can progress to active disease in their lifetime), delayed diagnosis and missed TB cases (~ 3 million), the latter two contributing to TB transmission (1). A 2015 retrospective analysis of 3220 TB patients diagnosed between 2005 and 2011 found that 25.7% of them had prior hospital visits for respiratory illness within a 90-day window preceding their TB diagnosis (3).

Smear microscopy, the commonly used test for the diagnosis of pulmonary TB (PTB) has poor sensitivity (4). Even though nucleic acid amplification tests such as GeneXpert have shown higher sensitivity in smear/culture positive cases, they perform poorly against composite reference standards (5). The execution of liquid culture tests, the gold standard for TB diagnosis, despite its accuracy has high turnover time and is extremely demanding in resource constrained settings (6). The painful invasive procedures to obtain clinical samples combined with its paucibacillary nature makes diagnosis of extrapulmonary TB (EPTB) all the more challenging. Relative to sputum samples, GeneXpert performs poorly in detecting bacilli in body fluids and aspirates (5, 7). If all these challenges associated with diagnosing TB can be overcome, effective treatment can be commenced early, reducing transmission and enhancing outcomes. Thus, a rapid and accurate diagnostic test will contribute significantly to controlling and eradicating TB in accordance with the END-TB Strategy (8).

Host based surrogate markers have been explored in recent times as a novel avenue for TB diagnosis. Activation (CD38, HLA-DR, CD127), differentiation (CD27, KLRG1), homing

(CCR4, CCR7) and proliferation (Ki-67) markers on *Mtb*-specific CD4⁺ T cells and their functional profiles (IFN- γ , TNF- α , IL-2, IL-10, IL-17) have been extensively explored to identify potential biomarkers for the diagnosis of TB (9–11). CD38, HLA-DR and Ki-67 on *Mtb*-specific CD4⁺IFN- γ ⁺ cells had impressive performance in discriminating LTBI from both PTB and EPTB and also in monitoring treatment response and assessing cure (12–16).

The robust cytokine TNF- α whose production at significantly higher frequencies makes its detection efficient has also been explored as a TB biomarker in numerous studies (9). The CD38⁺CD27[−] phenotype on CD4⁺ and on *Mtb*-specific CD4⁺IFN- γ ⁺ T cells has recently been shown to be dominant in active tuberculosis (aTB) (17). However, its biomarker performance was not evaluated. Here, we explored the ability of TNF- α secreting *Mtb*-specific CD38⁺CD27[−] CD4⁺ T cells to distinguish active from latent TB using PBMCs and validated its diagnostic performance in whole blood to enable translation into a field-compatible in vitro diagnostic test.

METHODS

Ethics statement: This study was carried out in accordance with the Declaration of Helsinki. Ethical clearance and necessary approvals were obtained from the Institutional Review Board of Indian Institute of Science (IISc), Bengaluru (5-14032018) and Employees State Insurance Corporation Medical College & Post Graduate Institute of Medical Sciences & Research (ESIC MC & PGIMSR), Bengaluru (532/L/11/12/Ethics/ESICMC&PGIMSR/Estt. Vol..III).

Study participants: 245 participants were recruited at ESIC MC & PGIMSR between Jan 2019 and Dec 2019. Written informed consent was obtained from all participants for the collection of samples and further analyses. 4 – 8mL blood was collected in sodium heparin prior to treatment initiation and matched sputum samples were collected wherever possible.

HIV+/HBV+ individuals were excluded from analysis. Recruitment of study participants has been outlined in Figure 1 and Table E1. Patient details have been summarised in Tables E2–4.

Antigens and antibodies: ESAT6/CFP10 peptides comprising 15mers with 11 amino acid overlap were procured from Synpeptide Co., Ltd (Shanghai, China). *Mtb*-cell wall antigen (*Mtb*-CW) was prepared as described previously (18, 19) and has been explained in detail in the online data supplement. The flow cytometry antibody panels used in the study are described in Table E5.

PBMC isolation, stimulation and flow cytometry: PBMCs were isolated by density gradient centrifugation on Histopaque®-1077 (Sigma-Aldrich) and suspended in RPMI-1640 medium containing 10% FBS, 2mM glutamine, 100 IU/ml penicillin, and 100mg/ml streptomycin. One million PBMCs or 0.5mL whole blood were stimulated with ESAT6/CFP10 peptide pool or *Mtb*-CW antigen at 10µg/mL in presence of brefeldin A (10µg/mL, Biolegend) for 20h at 37°C, 5% CO₂. Post incubation, PBMCs were first stained with Fixable Viability Stain 450 (FVS450, BD Biosciences) to discriminate live from dead cells, followed by appropriate surface markers. Cells were then fixed with 1% paraformaldehyde (10mins) and permeabilized with 0.1% saponin. Permeabilized cells were stained for appropriate intracellular markers and fixed with 0.5% paraformaldehyde before acquisition. For whole blood post antigen stimulation, RBCs were lysed and WBCs were fixed in a single lyse/fix step with 1mL of RBC lysis buffer (3% diethylene glycol, 1.875% - 2% formaldehyde and 0.5% - 0.75% methanol). The centrifuged cells were initially stained with FVS450 and then stained for both surface and intracellular markers in Buffer 2 (PerFix-nc kit; Beckman Coulter). The cells were then washed and resuspended in Buffer 3 (PerFix-nc kit; Beckman Coulter) prior to acquisition. Samples were acquired on Beckman Coulter DxFLEX flow cytometer and the data were analysed using CytExpert v2.0.

Statistical analysis: Antigen specific responses were considered positive if they met the following criteria: (i) a frequency $\geq 0.05\%$ in the stimulated tube and $\geq 0.03\%$ over the unstimulated control for TNF- α ; (ii) twice the frequency of that in the unstimulated control and $\geq 0.02\%$ over and above it for IFN- γ ; (iii) a frequency $\geq 0.02\%$ over the unstimulated control for IL-2. Additionally, responses were considered significant only if at least 15 events were recorded. Statistical analyses were performed using GraphPad Prism 6.

RESULTS

Activated and differentiated CD4⁺ T cell phenotypes are more prevalent in aTB

PBMCs from 56 subjects – 13 PTB, 13 EPTB, 15 cured TB (CTB) and 15 LTBI (Figure 1, Table 1 and Tables E1–3) were stimulated with ESAT6/CFP10 and *Mtb*-CW antigens. Gating strategy is shown in Figure E1. TNF- α responses from CD4⁺ T cells in the four groups are summarised in Figure 2. Despite a significant difference between EPTB and CTB upon ESAT6/CFP10 stimulation (Figure 2A), TNF- α ⁺CD4⁺ T cells could not differentiate aTB from non-TB groups (LTBI and CTB) in contrast to an earlier report (20). Surprisingly, 7 of the 15 individuals (46.67%) in the CTB group who had recently completed ATT had no significant CD4⁺TNF- α ⁺ production upon ESAT6/CFP10 stimulation along with 2 of the 13 (15.39%) in EPTB group. One individual in CTB group did not have significant response to either ESAT6/CFP10 or *Mtb*-CW antigen.

Expression of CD38⁺, CD27⁻, CD38⁺CD27⁻ and CD38⁻CD27⁺ was investigated on antigen specific TNF- α ⁺CD4⁺ T cells by multiparameter flow cytometry (Figure E2). Frequencies of candidate biomarkers on *Mtb*-specific cells were normalised to zero in non-responders and were not removed from analyses. We observed that significantly higher proportions of *Mtb*-specific TNF- α ⁺CD4⁺ T cells were phenotypically either CD38⁺, CD27⁻ or CD38⁺CD27⁻ in aTB compared to non-TB groups. In contrast, CD38⁻CD27⁺TNF- α ⁺CD4⁺ T cells were significantly

overrepresented in LTBI and CTB relative to aTB (Figure 3, A and B). In accordance with an earlier report (17), CD38⁺CD27⁻ frequencies on total CD4⁺ T cells were significantly higher in aTB while CD38⁻CD27⁺ was the predominant phenotype in non-TB groups (Figure 3C). Thus, these results indicate that activated and differentiated T cell phenotypes on total CD4⁺ and *Mtb*-specific TNF- α ⁺CD4⁺ T cells are associated with active disease.

CD38⁺CD27⁻TNF- α ⁺CD4⁺ T cells can detect active tuberculosis

Receiver operating characteristic (ROC) analysis was performed to evaluate the predictive value of CD38⁺TNF- α ⁺ (green), CD27⁻TNF- α ⁺ (red), CD38⁺CD27⁻TNF- α ⁺ (black) and CD38⁻CD27⁺TNF- α ⁺ (blue) in correctly classifying the TB and the non-TB groups and AUC values were determined (Figure 4, A and B). CD38⁺CD27⁻TNF- α ⁺ had the highest values for AUC with both ESAT6/CFP10 and *Mtb*-CW antigen stimulation - 0.93 and 0.94 respectively (Figure 4C). At a cut off value of 9.91%, CD4⁺CD38⁺CD27⁻ T cells secreting TNF- α accurately discriminated aTB from non-TB with a diagnostic accuracy of 92.86% with ESAT6/CFP10 stimulation (88.46% sensitivity and 96.67% specificity) and 91.07% with *Mtb*-CW stimulation (96.15% sensitivity and 86.67% specificity) (Figure 4D). When we excluded samples without significant responses from analysis as done in earlier reported studies, we obtained a much higher diagnostic accuracy of 95.74% (95.83% sensitivity and 95.65% specificity) with ESAT6/CFP10 stimulation (12, 21, 22). CD38⁺CD27⁻TNF- α ⁺ frequencies in CTB were comparable with those in LTBI, suggesting that this population would also serve to monitor treatment responses and assess cure (Figure 4D). Thus, CD38⁺CD27⁻TNF- α ⁺CD4⁺ T cells can accurately discriminate active TB irrespective of the disease site (both PTB and EPTB infections) from non-active states (LTBI and CTB).

Evaluation of predictive value of CD38⁺CD27⁻TNF- α ⁺ in an independent blinded cohort.

In order to validate the diagnostic performance of the candidate biomarker CD38⁺CD27⁻TNF- α ⁺CD4⁺ T cells, we resorted to the use of whole blood instead of PBMCs in a blinded cohort with the aim to enhance the utility of the test for field settings. The tedious and expertise-requiring process of PBMC isolation is challenging to conduct in resource limited clinical settings with high TB burden. In contrast, use of whole blood is economical, time saving, technically simple and amenable for translation into an in vitro diagnostic test. 165 subjects belonging to either PTB, EPTB, LTBI, healthy controls (HC) or sick controls (SC) were recruited as described in Figure 1 and Tables E1-4. Whole blood was stimulated with both ESAT6/CFP10 and *Mtb*-CW antigen followed by flow cytometry analyses as mentioned in Methods. Frequencies of CD38⁺CD27⁻TNF- α ⁺ in 48 and 14 individuals upon ESAT6/CFP10 and *Mtb*-CW stimulation respectively, where no significant CD4⁺TNF- α ⁺ production was observed were normalised to zero. Using the predetermined cut off value, we observed that following ESAT6/CFP10 stimulation, 59 individuals had CD38⁺CD27⁻TNF- α ⁺ frequencies above 9.91% and 106 individuals below it (Figure 5A). With *Mtb*-CW stimulation, 61 individuals had CD38⁺CD27⁻TNF- α ⁺ frequencies above 9.91% and 104 individuals below it (Figure 5B). When unblinded, we observed that ESAT6/CFP10-specific CD38⁺CD27⁻TNF- α ⁺ frequencies had correctly classified 55 of 61 aTB patients (36 of 41 PTB and 19 of 20 EPTB) and 100 of 104 non-TB individuals (31 of 32 LTBI, 30 of 33 SCs and 39 of 39 HCs) (Figure 5C and Table 2). *Mtb*-CW-specific CD38⁺CD27⁻TNF- α ⁺ frequencies correctly classified 49 of 61 aTB patients (30 of 41 PTB and 19 of 20 EPTB) and 92 of 104 non-TB individuals (31 of 32 LTBI, 26 of 33 SCs and 35 of 39 HCs) (Figure 5D and Table E6). Thus, CD38⁺CD27⁻TNF- α ⁺ frequencies correctly distinguished TB from non-TB with an accuracy of 93.94% with ESAT6/CFP10 stimulation (90.16% sensitivity and 96.15% specificity) and 85.45% with *Mtb*-CW stimulation (80.33% sensitivity and 88.46% specificity). However, *Mtb*-CW-specific CD38⁺CD27⁻TNF- α ⁺ had a better accuracy of 87.88% (88.52% sensitivity and 87.50%

specificity) at a cut off of 7.89% instead of 9.91% (Table E6). We then sought to render the test cost effective by confining the flow cytometry parameters to a single laser (5-parameter – CD3, CD4, CD27, CD38, TNF- α) by excluding the viability dye (FVS450) from analyses. The diagnostic accuracy was found to be 93.94% with ESAT6/CFP10 stimulation (91.80% sensitivity and 95.19% specificity) and 89.09% with *Mtb*-CW stimulation (88.52% sensitivity and 89.42% specificity) under these conditions (data not shown). Median frequencies of dead lymphocytes in the stimulated tubes were low (1.92%; Range – 0.90% to 9.50%) and ignoring the viability dye did not significantly alter the diagnostic performance.

Identification of additional biomarkers within mono and polyfunctional CD4⁺ T cell subsets

We further aimed to evaluate the diagnostic potential of CD38⁺CD27⁻, CD38⁺ and CD27⁻ phenotypes on *Mtb*-specific CD4⁺ T cells in combination with their cytokine (IFN- γ , TNF- α , IL-2) secretion profiles. The analyses were blinded and only candidate biomarkers having AUC values greater than 0.875 with both ESAT6/CFP10 and *Mtb*-CW stimulation were considered. When significant responders alone were considered for analysis, all potential biomarkers had better performance with ESAT6/CFP10 than with *Mtb*-CW stimulation. The results have been summarised in Table 2 and Table E6. In agreement with earlier reports, CD38⁺IFN- γ ⁺ correctly discriminated non-TB from aTB with sensitivity and specificity greater than 85% with both ESAT6/CFP10 and *Mtb*-CW stimulation in subjects with significant IFN- γ response (12, 13). CD38⁺TNF- α ⁺ and CD38⁺IL-2⁺ frequencies did not have a high discriminatory power (data not shown). However, CD38⁺IFN- γ ⁺TNF- α ⁺ had marginally better AUC values when compared to CD38⁺IFN- γ ⁺.

CD38⁺CD27⁻ phenotype on multiple additional functional outcomes had high diagnostic performance. Among all combinations, CD38⁺CD27⁻IFN- γ ⁺TNF- α ⁺ and CD38⁺CD27⁻IFN- γ ⁺

had the best diagnostic performance when only samples with significant responses were considered. The cytokine production (after background deduction) from *Mtb*-specific CD4⁺ T cells in whole blood is shown in Figure E2. Out of the 61 aTB patients, 58 had significant CD4⁺TNF- α ⁺ response, 43 had significant CD4⁺IFN- γ ⁺ response and only 36 had significant CD4⁺IL-2⁺ response with ESAT6/CFP10 stimulation (Table 2). With *Mtb*-CW stimulation, 57, 49 and 47 had significant CD4⁺TNF- α ⁺, CD4⁺IFN- γ ⁺ and CD4⁺IL-2⁺ response, respectively (Table E6). Due to the absence of significant IFN- γ and IL-2 response in whole blood in a high proportion of aTB subjects, biomarkers involving IFN- γ or IL-2 combinations are not feasible for use in clinical settings. Thus, the robust production of TNF- α makes it the cytokine of choice for discriminating aTB from non-TB individuals.

High prevalence of CD38⁻CD27⁺ phenotype in *Mtb*-exposed individuals without active disease

Frequencies of CD38⁻CD27⁺ phenotype on *Mtb*-specific CD4⁺ T cells defined by several functional outcomes were significantly higher in *Mtb*-exposed (LTBI, CTB and SC) subjects compared to aTB patients (Figure 4D, Figure 6 and Figure E4). Nevertheless, the considerable overlap evident between aTB and non-TB subjects precluded their use as reliable biomarkers. Since frequencies of CD38⁻CD27⁺ on *Mtb*-specific CD4⁺ T cells in CTB and SC groups were comparable with those in LTBI, these subsets could also be explored for monitoring treatment response and determining cure. Interestingly, in contrast to earlier reports (17) we did not observe CD38⁻CD27⁻ phenotype on *Mtb*-specific CD4⁺ T cells to be dominant in subjects who had completed ATT (data not shown).

DISCUSSION

In this study, we identified and validated *Mtb*-specific TNF- α secreting CD38⁺CD27⁻CD4⁺ T cells as a novel biomarker for diagnosis of aTB. We first identified this subset using PBMCs in

the exploratory cohort and further validated its performance in whole blood from an independent blinded cohort. To mimic the clinical setting we classified non responders as negative for the biomarker and retained them for analyses in contrast to other biomarker studies (12, 21, 22). Our study also included control subjects with other respiratory diseases who had previously completed ATT. The biomarker displayed impressive diagnostic accuracy in correctly distinguishing aTB (both PTB and EPTB) from non-TB groups (LTBI, SC, HC and CTB), testifying to its added potential for monitoring treatment response. It was especially heartening to note the reliability of the biomarker in correctly identifying EPTB patients where the difficulty in detecting bacilli makes diagnosis particularly challenging for the clinicians. Independent studies showing high frequencies of CD38⁺ and CD27⁻ on *Mtb*-specific CD4⁺ T cells in subjects co-infected with TB and HIV, suggest the utility of this biomarker also in these individuals (13–15, 23).

CD38⁺CD27⁻CD4⁺ T cells secreting IFN- γ or IL-2 alone or in combination with each other or with TNF- α and CD38⁺ on polyfunctional CD4⁺ T cells had high predictive power in discriminating aTB from non-TB (Table 2 and Table E6). However, their absence in a considerable proportion of subjects precluded their choice as useful biomarkers of TB disease. Multiple previously characterised host immune biomarkers such as CD27⁻ phenotype on IFN- γ ⁺TNF- α ⁺CD4⁺ T cells (10), CD27⁻ phenotype on IFN- γ ⁺CD4⁺ T cells (10, 24, 25), and monofunctional and polyfunctional CD4⁺ T cells (20, 26–28) did not effectively distinguish non-TB groups from aTB in our validation cohort using whole blood and had AUC values considerably below 0.875.

CD38⁺IFN- γ ⁺, HLA-DR⁺IFN- γ ⁺ and Ki-67⁺IFN- γ ⁺ have shown high diagnostic performance in discriminating latent from active TB in several independent studies (12–16). CD38⁺IFN- γ ⁺ had high predictive power when we considered only samples with significant IFN- γ responses (Table 2 and Table E6). Recently, Musvosvi *et al.* using whole blood showed that HLA-DR⁺

and HLA-DR⁺CD27⁻ phenotypes on antigen-specific CD4⁺ T cells secreting IFN- γ or TNF- α or IL-2 alone or in combination with each other had high sensitivity and specificity for TB diagnosis. Additionally they reported that a simple four colour flow cytometry panel comprising CD3, HLA-DR, IFN- γ and TNF- α was sufficient to discriminate latent from aTB (21). Despite their high sensitivity and specificity, the exclusion of non-responders from analyses calls into question the utility of these biomarkers in a field setting. By including all the non-responders in the analyses, our data represent a truly realistic picture of the diagnostic accuracy of the identified biomarker in a clinical setting.

Flow cytometry is today commonplace in diagnostic laboratories enabling the exploitation of host blood-based biomarkers for disease diagnosis. Our results affirm the potential of phenotypic biomarkers on *Mtb*-specific CD4⁺ T cells defined by production of TNF- α rather than IFN- γ or IL2 to be a superior and robust biomarker. Identification of the unique CD4⁺ T cell subset with CD38⁺CD27⁻ phenotype allowed us to exploit the potential of the abundant cytokine TNF- α to correctly identify both pulmonary and extra-pulmonary tuberculosis with high predictive values in whole blood assays that can be performed with a single laser 5-parameter flow cytometer.

ACKNOWLEDGMENTS

We sincerely thank all the study participants, ESIC MC & PGIMSR staff and healthcare workers of RNTCP (Revised National Tuberculosis Control Programme presently National Tuberculosis Elimination Programme (NTEP))-Hosahalli TB Unit. This work was funded by DBT-IISc Partnership Program Phase-II (BT/PR27952/INF/22/212/2018). The funding agency had no role in the study. We gratefully acknowledge Beckman Coulter India Private Limited for providing flow cytometer, antibodies, reagents and salary for MPA. We thank the Biosafety Level-3 (BSL-3) facility at IISc.

DECLARATION OF INTERESTS

VS received grants from Department of Biotechnology, Government of India (BT/PR23695/MED/29/1195/2017 Dated 28/12/2017) and Beckman Coulter India Private Limited (SP/BECO-16-0001) outside the submitted work. MPA received salary from Beckman Coulter India Private Limited outside the submitted work.

DATA AVAILABILITY

Study protocols, exported flow cytometry data and de-identified FCS files that underlie the results reported are available from the corresponding author upon reasonable request.

AUTHOR CONTRIBUTIONS

VS conceived the study, supervised and edited the manuscript. MPA designed, planned, conducted the experiments, analysed and interpreted data and wrote the manuscript. SPP assisted with PBMC processing in exploratory cohort. VSM, PC, VK, SN, SBN, N, RY were responsible for diagnosis, consenting and recruitment of patients, clinical sample collection and maintenance of case records and reports.

REFERENCES

1. World Health Organization(WHO). Global tuberculosis report 2019. <https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1> (accessed 15 May, 2020).
2. Central TB Division, Government of India (GOI). Nikshay database. <https://reports.nikshay.in/> (accessed 15 May, 2020).

3. Miller AC, Polgreen LA, Cavanaugh JE, Hornick DB, Polgreen PM. Missed opportunities to diagnose tuberculosis are common among hospitalized patients and patients seen in emergency departments. *Open Forum Infect Dis* 2015; 2:ofv171.
4. Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart KR. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; 13:147–54.
5. Li S, Liu B, Peng M, Chen M, Yin W, Tang H, Luo Y, Hu P, Ren H. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. *PloS One* 2017; 12:e0180725.
6. Parsons LM, Somoskövi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, Spector S, Roscigno G, Nkengasong J. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. *Clinical microbiology reviews* 2011; 24:314–50.
7. Tadesse M, Abebe G, Bekele A, Bezabih M, Yilma D, Apers L, de Jong BC, Rigouts L. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a diagnostic evaluation study. *Clin Microbiol Infect.* 2019; 25:1000–05.
8. World Health Organization(WHO). END TB Strategy and targets. 2014. https://www.who.int/tb/End_TB_brochure.pdf (accessed 23 July, 2020).
9. Yong YK, Tan HY, Saeidi A, Wong WF, Vignesh R, Velu V, Eri R, Larsson M, Shankar EM. Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects. *Front Microbiol* 2019; 10:2789.
10. Latorre I, Fernández-Sanmartín MA, Muriel-Moreno B, Villar-Hernández R, Vila S, Souza-Galvão ML, Stojanovic Z, Jiménez-Fuentes MÁ, Centeno C, Ruiz-Manzano J, Millet JP, Molina-Pinargote I, González-Díaz YD, Lacomá A, Luque-Chacón L, Sabriá J, Prat C, Domínguez J. Study of CD27 and CCR4 Markers on Specific CD4(+) T-Cells

- as Immune Tools for Active and Latent Tuberculosis Management. *Front Immunol* 2018; 9:3094.
11. Lichtner M, Mascia C, Sauzullo I, Mengoni F, Vita S, Marocco R, Belvisi V, Russo G, Vullo V, Mastroianni CM. Multifunctional Analysis of CD4⁺ T-Cell Response as Immune-Based Model for Tuberculosis Detection. *J Immunol Res* 2015; 2015:217287.
 12. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM, Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. *J Clin Invest* 2015; 125:1827–38.
 13. Silveira-Mattos PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, Vinhaes CL, Oliveira-de-Souza D, Ibegbu CC, Figueiredo MC, Sterling TR, Rengarajan J, Andrade BB. Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4⁺ T-cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection. *Clin Infect Dis* 2019; doi:[10.1093/cid/ciz1070](https://doi.org/10.1093/cid/ciz1070).
 14. Wilkinson KA, Oni T, Gideon HP, Goliath R, Wilkinson RJ, Riou C. Activation Profile of Mycobacterium tuberculosis-Specific CD4(+) T Cells Reflects Disease Activity Irrespective of HIV Status. *Am J Respir Crit Care Med* 2016; 193:1307–10.
 15. Riou C, Berkowitz N, Goliath R, Burgers WA, Wilkinson RJ. Analysis of the Phenotype of Mycobacterium tuberculosis-Specific CD4⁺ T Cells to Discriminate Latent from Active Tuberculosis in HIV-Uninfected and HIV-Infected Individuals. *Front Immunol* 2017; 8:968.
 16. Riou C, Gray CM, Lugongolo M, Gwala T, Kiravu A, Deniso P, Stewart-Isherwood L, Omar SV, Grobusch MP, Coetzee G, Conradie F, Ismail N, Kaplan G, Fallows D. A Subset of Circulating Blood Mycobacteria-Specific CD4 T Cells Can Predict the Time to Mycobacterium tuberculosis Sputum Culture Conversion. *PLoS One* 2014; 9:e102178.

17. Ahmed MIM, Ntinginya NE, Kibiki G, Mtafya BA, Semvua H, Mpagama S, Mtabho C, Saathoff E, Held K, Loose R, Kroidl I, Chachage M, von Both U, Haule A, Mekota AM, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N, Geldmacher C. Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy. *Front Immunol* 2018; 9:2247.
18. Hirschfield GR, McNeil M, Brennan PJ. Peptidoglycan-associated polypeptides of Mycobacterium tuberculosis. *J. Bacteriol* 1990; 172:1005–13.
19. Rabodoarivelo MS, Aerts M, Vandamme P, Palomino JC, Rasolofo V, Martin A. Optimizing of a protein extraction method for Mycobacterium tuberculosis proteome analysis using mass spectrometry. *J Microbiol Methods* 2016; 131:144–47.
20. Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jatton K, Faouzi M, Day CL, Hanekom WA, Bart PA, Pantaleo G. Dominant TNF- α ⁺ Mycobacterium tuberculosis-specific CD4⁺ T cell responses discriminate between latent infection and active disease. *Nat Med* 2011; 17:372–76.
21. Musvosvi M, Duffy D, Filander E, Africa H, Mabwe S, Jaxa L, Bilek N, Llibre A, Rouilly V, Hatherill M, Albert M, Scriba TJ, Nemes E. T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. *Eur Respir J* 2018; 51:1800153.
22. Pollock KM, Whitworth HS, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, Kon OM, Sampson RD, Taylor GP, Lalvani A. T-cell immunophenotyping distinguishes active from latent tuberculosis. *J Infect Dis* 2013; 208:952–68.
23. Schuetz A, Haule A, Reither K, Ngwenyama N, Rachow A, Meyerhans A, Maboko L, Koup RA, Hoelscher M, Geldmacher C. Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo. *PLoS One* 2011; 6:e27284.

24. Streitz M, Tesfa L, Yildirim V, Yahyazadeh A, Ulrichs T, Lenkei R, Quassem A, Liebetrau G, Nomura L, Maecker H, Volk HD, Kern F. Loss of receptor on tuberculin-reactive T-cells marks active pulmonary tuberculosis. *PloS One* 2007; 2:e735.
25. Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya NE, Mfinanga E, Said K, Haraka F, Rachow A, Saathoff E, Mpina M, Jugheli L, Lwilla F, Marais BJ, Hoelscher M, Daubenberger C, Reither K, Geldmacher C. Assessment of the novel T-cell activation marker–tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. *Lancet Infect Dis* 2014; 14:931–38.
26. Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, Dosanjh DP, Guyot-Revol V, Gunatheesan R, Klenerman P, Lalvani A. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. *J Immunol* 2007; 178:5217–26.
27. Sargentini V, Mariotti S, Carrara S, Gagliardi MC, Teloni R, Goletti D, Nisini R. Cytometric detection of antigen-specific IFN-gamma/IL-2 secreting cells in the diagnosis of tuberculosis. *BMC Infect Dis* 2009; 9:99.
28. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, Galati D, Bocchino M, Matarese A, Salerno A, Sanduzzi A, Franken WP, Ottenhoff TH, Dieli F. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. *Eur J Immunol* 2010; 40:2211–20.

Figure 1

Figure 1. CONSORT flow diagram of recruited patients. 245 individuals were recruited for the study in two separate cohorts: exploratory and validation. The recruited individuals belonged to one of the following groups as indicated - pulmonary tuberculosis (PTB), extrapulmonary tuberculosis (EPTB), latent tuberculosis infection (LTBI), healthy controls (HC), cured tuberculosis (CTB) or sick controls (SC). HBV: Hepatitis B virus, HIV: Human immunodeficiency virus, IBV: insufficient blood volume.

Figure 2

Figure 2. Frequencies of TNF- α secreting CD4⁺ T cells in the exploratory cohort.

PBMCs from treatment naive PTB (n = 13) and EPTB (n = 13) subjects, LTBI (n = 15) and CTB (n = 15) were stimulated with (A) ESAT6/CFP10 and (B) *Mtb*-CW antigens and analysed by flow cytometry. CD4⁺TNF- α ⁺ frequencies are reported after subtracting the unstimulated response from the stimulated tubes. Kruskal-Wallis test followed by Dunn's post-test was used to compare the groups: **p < 0.01. Filled symbols indicate samples with no-significant CD4⁺TNF- α ⁺ response. Bars represent medians.

Figure 3

Figure 3. Expression of phenotypic markers on *Mtb*-specific $\text{TNF-}\alpha^+\text{CD4}^+$ and total CD4^+ T cells.

CD38^+ , CD27^- , $\text{CD38}^+\text{CD27}^-$ and $\text{CD38}^-\text{CD27}^+$ phenotypes on $\text{TNF-}\alpha^+\text{CD4}^+$ T cells were analysed in PBMCs stimulated with (A) ESAT6/CFP10 and (B) *Mtb*-CW antigens from 26 individuals with aTB (circles) (13 PTB and 13 EPTB) and 30 individuals from non-TB groups (squares) (15 LTBI and 15 CTB). Frequencies of *Mtb*-specific $\text{TNF-}\alpha^+\text{CD4}^+$ T cells with different phenotypic markers were normalised to 0% in samples with no significant $\text{TNF-}\alpha$ production. (C) Phenotypic characteristics on total CD4^+ T cells in non-stimulated PBMCs. Data were analysed using Mann-Whitney *U* test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, ns: non-significant. Bars represent median values.

Figure 4

Figure 4. Evaluation of diagnostic performance of phenotypic markers on *Mtb*-specific TNF- α ⁺CD4⁺ T cells in exploratory cohort.

Receiver Operating Characteristics (ROC) curve analyses of CD38⁺ (green), CD27⁻ (red), CD38⁺CD27⁻ (black) and CD38⁻CD27⁺ (blue) phenotypes on *Mtb*-specific TNF- α ⁺CD4⁺ T cells was used to determine their ability to discriminate aTB from non-TB groups upon (A) ESAT6/CFP10 and (B) *Mtb*-CW antigen stimulation. Dotted line represents the line of identity.

AUC: area under the curve and CI: confidence interval **(C)** Diagnostic performance of the four biomarkers upon ESAT6/CFP10 (circle) and *Mtb*-CW antigen (square) stimulation. Dotted blue lines represent 85% sensitivity and specificity. **(D)** Frequencies of CD38⁺CD27⁻TNF- α ⁺ in PBMCs stimulated with ESAT6/CFP10 and *Mtb*-CW antigen from individuals in the following categories: PTB (n = 13), EPTB (n = 13), LTBI (n = 15) and CTB (n = 15). CD38⁺CD27⁻TNF- α ⁺ frequencies in samples with insignificant CD4⁺TNF- α ⁺ response were normalised to 0%. The red dashed line represents the discriminatory cut-off value of 9.91%. Bars represent medians.

Figure 5

Figure 5. Frequencies of CD38⁺CD27⁻TNF-α⁺ in the validation cohort.

Frequencies of CD38⁺CD27⁻TNF-α⁺ from 165 individuals in **(A)** ESAT6/CFP10 and **(B)** *Mtb*-CW antigen stimulated whole blood have been summarised. The predetermined cut-off value of 9.91% is indicated by the dashed line. Frequencies of CD38⁺CD27⁻TNF-α⁺ were normalised to 0% in samples with no significant CD4⁺TNF-α⁺ response. Filled circles and hollow squares correspond to individuals from aTB (PTB and EPTB) and non-TB groups (LTBI, HC, SC) respectively, after unblinding. Frequencies of CD38⁺CD27⁻TNF-α⁺ from PTB (n = 41), EPTB (n = 20), LTBI (n = 32), HC (n = 39) and SC (n = 33) upon **(C)** ESAT6/CFP10 and **(D)** *Mtb*-CW antigen have been summarized, after unblinding. Black dashed line represents the predetermined cut-off value of 9.91%.

Figure 6

Figure 6. Frequencies of CD38⁻CD27⁺ on *Mtb*-specific on mono and polyfunctional CD4⁺ T cells.

CD38⁻CD27⁺ frequencies on *Mtb*-specific CD4⁺ T cells upon stimulation with ESAT6/CFP10 were significantly higher in *Mtb*-exposed individuals (LTBI and SC) compared to individuals with aTB (PTB and EPTB). Only samples with significant cytokine responses have been analysed. The number of responders for each cytokine or their combination have been summarised in Table 2 and Table E6. Mann-Whitney *U* test was used to compare the two groups for each functional outcome: *****p* < 0.0001. Bars represent medians.

Table 1

		Study population			Eligible patients not included in the study		
		<i>n</i>	<i>Males (%)</i>	<i>Median Age(y) (Range)</i>	<i>n</i>	<i>Males (%)</i>	<i>Median Age(y) (Range)</i>
<i>Exploratory cohort</i>	PTB	13	62	44 (17 - 65)	22	73	44 (17 - 65)
	EPTB	13	54	37 (21 - 64)	38	41	30.5 (15 - 59)
	LTBI	15	60	40 (20 - 57)			
	CTB	15	87	40 (24 - 57)			
<i>Validation cohort</i>	PTB	41	73	45 (22 - 63)	27	67	41 (15 - 65)
	EPTB	20	45	31.5 (18 - 50)	61	43	35 (15 - 65)
	SC	33	64	45 (23 - 65)	111	69	51 (20 - 65)
	LTBI	32	53	33.5 (18 - 52)			
	HC	39	69	38 (18 - 56)			

Table 1. Characteristics of the study population. The characteristics have been compiled for patients whose samples were included for analysis. PTB: pulmonary tuberculosis, EPTB: extrapulmonary tuberculosis, LTBI: latent tuberculosis infection, HC: healthy controls, CTB: cured tuberculosis and SC: sick controls.

Table 2

Phenotype		CD38 ⁺ CD27 ⁻												CD38 ⁺																			
Functional Profile	TNF- α ⁺	IL-2 ⁺		IFN- γ ⁺		IFN- γ ⁺ IL-2 ⁺		IFN- γ ⁺ TNF- α ⁺		IL-2 ⁺ TNF- α ⁺		IFN- γ ⁺ OR IL-2 ⁺ OR TNF- α ⁺		IFN- γ ⁺	IFN- γ ⁺ IL-2 ⁺	IFN- γ ⁺ TNF- α ⁺	IL-2 ⁺ TNF- α ⁺	IFN- γ ⁺ IL-2 ⁺ TNF- α ⁺															
Cut off	> 9.91	> 5.94		> 11.25		> 7.96		> 11.81		> 7.71		> 8.10		> 8.440		> 9.83		> 7.86		> 7.68		> 26.51		> 22.83		> 26.67		> 22.41		> 22.83			
Samples with significant cytokine response																																	
		R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR		
TB	PTB	39	2	22	19	31	10	19	22	31	10	21	20	19	22	24	17	37	4	33	8	33	8	31	10	19	22	31	10	21	20	19	22
	EPTB	19	1	14	6	12	8	11	9	12	8	14	6	11	9	12	8	19	1	16	4	16	4	12	8	11	9	12	8	14	6	11	9
non-TB	LTBI	28	4	23	9	30	2	22	10	27	5	23	9	21	11	23	9	31	1	25	7	26	6	30	2	22	10	27	5	23	9	21	11
	HC	11	28	14	25	0	39	0	39	0	39	6	33	0	39	7	32	12	27	16	23	15	24	0	39	0	39	0	39	6	33	0	39
	SC	20	13	14	19	16	17	12	21	16	17	12	21	12	21	15	18	21	12	20	13	21	12	16	17	12	21	16	17	12	21	12	21
AUC		0.9687		0.9235		0.9707		0.9706		0.9754		0.9199		0.9677		0.9574		0.9675		0.9369		0.9396		0.9237		0.9206		0.9446		0.8875		0.9237	
P-value		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001			
Sensitivity(%)		94.83		83.33		95.35		93.33		95.35		85.71		93.33		91.67		92.86		89.8		91.84		90.7		83.33		88.37		85.71		83.33	
Specificity(%)		93.22		94.12		95.65		97.06		95.35		97.56		96.97		93.33		95.31		90.16		90.32		89.13		94.12		90.7		90.24		93.94	
Accuracy(%)		94.02		89.66		95.51		95.31		95.35		92.1		93.65		92.59		94.16		90		90.99		89.89		89.06		89.54		88.15		87.3	
All tested samples (PTB – 41; EPTB – 20; LTBI – 32; HC – 39; SC – 33)																																	
(Samples with insignificant cytokine response were considered negative for the respective biomarker and their values were normalised to zero)																																	
AUC		0.9462		0.6959		0.7937		0.6972		0.8013		0.7129		0.6969		0.7113		0.9186		0.8156		0.8164		0.7634		0.6623		0.7781		0.6839		0.6656	
P-value		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		0.004			
Sensitivity(%)		90.16		49.18		67.21		45.9		67.21		49.18		45.9		54.1		85.25		72.13		73.77		63.93		40.98		62.3		49.18		40.98	
Specificity(%)		96.15		97.12		98.08		99.04		98.08		99.04		99.04		97.12		97.12		94.23		94.23		95.19		98.07		96.15		96.15		98.08	
Accuracy(%)		93.94		79.39		86.67		79.39		86.67		80.61		79.39		81.22		92.73		86.06		86.67		83.63		76.97		83.64		78.79		76.36	

Table 2. Biomarker performance of CD38⁺CD27⁻ and CD38⁺ within mono- and polyfunctional CD4⁺ T cells.

Diagnostic potentials of several biomarkers with AUC values > 0.875 in ESAT6/CFP10 stimulated whole blood have been summarised. Number of samples with significant responses for each cytokine or their combination have been listed. For AND combinations, response was considered significant if all the cytokines involved in the combination were independently significant. For OR combinations, criteria for significant responses were same as that for TNF- α . To counter the problem of insignificant cytokine responses in whole blood, OR combinations were evaluated to check if antibodies for 2 or more cytokines could be used in the same detector channel. Mann Witney *U* test was used to compare the TB (PTB and EPTB) and non-TB (LTBI, HC and SC) groups. AUC: area under the curve.

ONLINE DATA SUPPLEMENT

List of Supplementary Materials

Supplemental Methods

Figure E1. Gating Strategy.

Figure E2. Representative flow plots showing phenotypic characteristics of *Mtb*-specific TNF- α ⁺CD4⁺ T cells upon stimulation with ESAT6/CFP10 and *Mtb*-CW antigens.

Figure E3. Analysis of cytokine secreting *Mtb*-specific CD4⁺ T cells.

Figure E4. Frequencies of CD38⁻CD27⁺ on *Mtb*-specific on mono and polyfunctional CD4⁺ T cells.

Table E1: Description of study participants.

Table E2: Clinical description of pulmonary tuberculosis patients included in the study.

Table E3: Clinical description of extrapulmonary tuberculosis patients included in the study.

Table E4: Clinical description of sick controls in the study.

Table E5. Summary of the antibody panels used in the study.

Table E6. Biomarker performance of CD38⁺CD27⁻ and CD38⁺ within mono- and polyfunctional CD4⁺ T cells.

SUPPLEMENTAL METHODS

Preparation of *Mtb*-cell wall (*Mtb*-CW) antigen: *Mtb*-CW was prepared as described previously (E1, E2). Briefly, bacteria (H37Rv) grown to late log phase (14 days) were heat killed at 80°C for 1h. Cells were pelleted at 5000 x g, washed four to five times with PBS and suspended at a concentration of 0.5g/mL in PBS containing 3mM EDTA, DNase (1mg/mL; Sigma, D5025), RNase (1mg/mL; Sigma, R4875) and protease inhibitor cocktail (Sigma, P8465). The cells were disrupted with 0.1mm zirconia beads in FastPrep-24 (MP Biomedicals, LLC) at 4.5m/s for 1min followed by 2mins rest on ice for 8 cycles. The beads were allowed to settle and the collected supernatant was sonicated in a Branson 250/450 sonifier at 30% amplitude for 2mins with 5mins rest on ice for 8 cycles. The lysate was centrifuged at 5000 x g twice to remove partially broken/unbroken cells. The supernatant was centrifuged at 27000 x g (4°C) for 1h and the cell wall pellet was resuspended and dialysed (3500 MWCO) in 10mM ammonium bicarbonate for 24h at 4°C with three buffer changes and quantified by Bradford's assay. Protein quality of the *Mtb*-CW fraction was assessed by SDS-PAGE and silver staining.

Figure E1

Figure E1. Gating Strategy. Lymphocytes were obtained using Forward Scatter Area (FSC-A) versus Side Scatter Area (SSC-A) followed by singlets from Forward Scatter-Height and FSC-A. Dead lymphocytes were excluded and the CD3⁺CD4⁺ population was selected from live lymphocytes that was obtained from the NOT (Dead Lymphocytes) population. TNF-α producing CD4⁺ T cells were selected and were displayed on CD27 vs CD38. The same quadrant gate on CD27 vs CD38 on total CD4⁺ T cells was applied to CD27 vs CD38 on CD4⁺TNF-α⁺ T cells using the “Link Gate” feature in CytExpert v2.0. CD38⁺TNF-α⁺: (Q5 + Q6), CD27⁺TNF-α⁺: (Q5+Q7), CD38⁺CD27⁺TNF-α⁺: Q5 and CD38⁺CD27⁺TNF-α⁺: Q7.

Figure E2

Figure E2. Representative flow plots showing phenotypic characteristics of *Mtb*-specific $\text{TNF-}\alpha^+\text{CD4}^+$ T cells upon stimulation with ESAT6/CFP10 and *Mtb*-CW antigens.

Figure E3

Figure E3. Analysis of cytokine secreting Mtb-specific CD4⁺ T cells.

Whole blood from PTB (n= 41), EPTB (n = 20), LTBI (n = 32), HC (n = 39) and SC (n = 33) were stimulated with ESAT6/CFP10 (**A, C, E**) or *Mtb*-CW antigen (**B, D, F**). Frequencies of CD4⁺TNF- α ⁺ (**A, B**), CD4⁺IFN- γ ⁺ (**C, D**), CD4⁺IL-2⁺ (**E, F**) are reported after subtracting the unstimulated response from the stimulated tubes. Kruskal-Wallis test followed by Dunn's post-test was used to compare the groups: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Samples with no-significant cytokine response are highlighted using filled symbols. Bars represent medians.

Figure E4

Figure E4. Frequencies of CD38⁻CD27⁺ on *Mtb*-specific on mono and polyfunctional CD4⁺ T cells.

CD38⁻CD27⁺ frequencies on *Mtb*-specific CD4⁺ T cells upon stimulation with *Mtb*-CW were significantly higher in *Mtb*-exposed individuals (squares) (LTBI and SC) compared to individuals with aTB (circles) (PTB and EPTB). Only samples with significant cytokine responses have been analysed. The number of responders for each cytokine or their combination have been summarised in Table 2 and Table E6. Mann-Whitney *U* test was used to compare the two groups for each functional outcome: ****p* < 0.001, *****p* < 0.0001. Bars represent medians.

Table E1: Description of study participants.

Exploratory cohort (EC)	79 participants recruited were categorised into four groups: 15 having PTB (2 excluded from analysis – 1 HBV+, 1 insufficient blood volume), 15 with EPTB (2 excluded from analysis – insufficient blood volume) , 16 cured patients (1 excluded from analysis – TB relapse) and 33 healthy individuals out of which 16 were found to be latently infected with <i>Mtb</i> (1 excluded from analysis – insufficient blood volume).
Validation cohort (VC)	166 participants recruited randomly and were categorised post analysis as follows: 41 having PTB, 21 with EPTB (1 excluded from analysis – HIV+), 33 sick controls previously treated for TB and 71 healthy individuals out of which 32 were found to be latently infected with <i>Mtb</i> .
Pulmonary tuberculosis patients (PTB)	Subjects recruited were either positive for sputum AFB or for PCR (Xpert-MTB/RIF - Cepheid) or both. Subsequent culture of sputum revealed all recruited cases to be culture positive. In most cases, First Line – Line Probe Assay (GenoType MTBDRplus V2 - Hain Lifescience GmbH) was performed to detect Rifampicin and Isoniazid resistance.
Extrapulmonary tuberculosis patients (EPTB)	EPTB cases were confirmed by at least one of the following tests in addition to the clinical diagnosis: ZN stain (aspirates/biopsies), FNAC/FNAB (aspirates/ biopsies), PCR - Xpert-MTB/RIF (body fluids/ aspirates/ biopsies), or predominant lymphocyte infiltration and ADA levels > 40U/mL (pleural fluid and ascites). Disease sites included lymph node, pleural fluid, brain, urinary bladder/ureter, ovary/fallopian tube,

	peritoneal cavity, intestine and eye. Extrapulmonary infections associated with pulmonary infections were not recruited.
Latently infected subjects (LTBI) and healthy controls (HC)	Health care workers at ESIC MC & PGIMSR, Revised National Tuberculosis Control Programme (RNTCP) presently National Tuberculosis Elimination Programme (NTEP) staff of Hosahalli TB unit and <i>Mtb</i> exposed household contacts with no symptoms of the disease and no previous history of tuberculosis were screened for latent TB infection. IGRA+ subjects or individuals with significant ESAT6/CFP10-specific IFN- γ ⁺ CD4 ⁺ T cell responses in 20hr stimulated whole blood were classified as latent TB. The non-responders were categorised as <i>healthy controls (HC)</i> and in the exploratory cohort were not processed further.
Cured TB subjects (CTB)	Recently treated PTB patients who had completed ATT in the past 1 – 2 months with sputum negative for smear AFB and culture were recruited.
Previously treated sick controls (SC)	Patients who had previously completed ATT for PTB at least 1 year prior and presenting themselves at the hospital with chest/lung infection having clinical symptoms of TB were recruited. They were all sputum smear negative and completely recovered from their symptoms within 10 - 15 days of antibiotic/antifungal/antiviral treatment. All these sputum cultures were negative.

Table E2: Clinical description of pulmonary tuberculosis patients included in the study.

ID	Age	Sex	Symptoms	AFB	PCR (Rif)	FL-LPA (Rif, Inh)	Culture
Exploratory cohort							
P1	65	M	cough, weight loss, fatigue, extensive non homogenous opacities in right lung	1+	+ (S)	..	+
P2	35	M	cough, fever, weight loss, night sweats, nodules in the lungs	1+	+ (S)	+ (S, S)	+
P3	29	F	cough, fever, weight loss, lassitude, chest pain, left pleural effusion	3+	+ (S)	+ (S, S)	+
P4	49	M	cough, fever, chest pain, left pleural effusion	3+	+ (S)	+ (S, S)	+
P5	50	M	cough, fever, weight loss, night sweats, chills, consistent non homogenous opacities in the lungs	2+	+ (S)	..	+
P6	44	M	cough, fever, weight loss, hemoptysis	2+	+ (S)	..	+
P7	55	F	cough, fever, weight loss, lassitude, throat pain, cavitary lesion in the left lower lobe	2+	+ (S)	+ (S, S)	+
P8	30	F	cough, fever, weight loss, weakness, fatigue, nodular densities in the left lung	2+	+ (S)	+ (S, S)	+

P9	44	F	cough, fever, weight loss, lassitude, chest pain, cavitation in right middle lobe	3+	+ (S)	+ (S, S)	+
P11	65	M	cough, fever, weight loss, lassitude, bilateral cavitory lesions in the lower lobes	2+	+ (S)	+ (S, S)	+
P12	48	M	cough, fever, chest pain, hemoptysis, pleural effusion in left lung, multiple cavitory lesions in right upper and middle lobes	3+	..	..	+
P13	28	M	cough, weight loss, chest pain, fatigue, cavitory lesion in right upper lobe	2+	+ (S)	+ (S, S)	+
P14	17	F	productive cough, evening rise of temperature, cavitation in right lower and middle lobes	2+	+ (R)	<i>SL LPA:</i> + (FQ: S, K: R)	+
Validation cohort							
P15	48	M	intermittent fever, cough, chest pain, weight loss, loss of appetite, bilateral cavitation in lower lobes	3+	+ (S)	+ (S, S)	+
P16	48	M	cough, fever, weight loss, night sweats, loss of appetite, weakness, consistent non homogenous opacities in the lungs, right pleural effusion	3+	+ (S)	+ (S, S)	+

P17	45	M	cough, fever with chills, weight loss, headache, nausea, loss of appetite, nodular densities in both the lungs	3+	+ (S)	+ (S, S)	+
P18	41	M	cough, fever, hemoptysis, chest pain, weight loss, loss of appetite, nodular densities in both the lungs, multiple cavitory lesions in right lung	3+	+ (S)	..	+
P19	28	F	persistent cough, pain in the right eye (chronic uveitis), consistent non-homogenous opacities the lungs, nodules in the right upper lobe	Neg	+ (S)	..	+
P20	52	M	cough, fever, weight loss, chest pain, bilateral cavitation in middle lobes	3+	+ (S)	+ (S, S)	+
P21	42	M	cough, fever, weight loss, night sweats, cavitation in right middle and lower lobes, left pleural effusion	1+	+ (S)	+ (S, S)	+
P22	40	F	cough, fever, weight loss consistent non homogenous opacities in the lung, pleural effusion	1+	+ (S)	+ (S, S)	+
P23	41	M	evening rise of temperature, chest pain, weight loss, loss of appetite, night sweats	2+	+ (S)	+ (S, S)	+
P24	63	M	cough, fever, weight loss, loss of appetite, cavitory lesion in the left middle lobe	3+	+ (S)	..	+

P25	50	M	cough, fever, hemoptysis, weight loss, bilateral cavitation in middle lobes	3+	+ (S)	+ (S, S)	+
P26	52	M	cough, fever with chills, weight loss, chest pain, loss of appetite, complete destruction of left lung, non-homogenous opacities in the right lung	3+	+ (S)	+ (S, S)	+
P27	37	M	cough, fever, weight loss, loss of appetite, small nodular densities in the lungs	1+	+ (S)	+ (S, S)	+
P28	22	M	productive cough, fever	3+	+ (S)	+ (S, S)	+
P29	58	M	cough, fever, weight loss, chest pain, cavitation in left middle and upper lobes	2+	+ (S)	+ (S, S)	+
P30	60	M	cough, fever, weight loss, chest pain, loss of appetite, calcified nodules and cavitory lesions in the left lower lobe	3+	+ (S)	+ (S, S)	+
P31	39	M	cough, fever, cavitory lesions in the left upper and middle lobe	1+	+ (S)	+ (S, S)	+
P32	45	M	cough, fever, weight loss, headache, body pain, lassitude	Neg	+ (S)	+ (S,R)	+
P33	46	F	productive cough, chest pain, left pleural effusion	Neg	+ (S)	+ (S,R)	+

P34	26	F	cough, chest pain, weight loss, loss of appetite, headache, lassitude, cavitation in upper right lobe	3+	+ (S)	+ (S, S)	+
P35	50	M	persistent cough, weight loss, multiple cavitory lesions in the left lung	2+	+ (S)	+ (S, S)	+
P36	26	F	cough, fever, weight loss, loss of appetite, consistent non homogenous opacities in the lung	3+	+ (S)	+ (S, S)	+
P37	44	F	cough, fever accompanied with chills, night sweat, loss of appetite, calcified nodules in the left lower and middle lobe	2+	+ (S)	+ (S, S)	+
P38	49	M	cough, weight loss, lassitude, pulmonary infiltrates in the right lung	3+	+ (S)	+ (S, S)	+
P39	30	F	fever, chills, night sweats, weight loss, loss of appetite, chest pain, multiple cavitory lesions in the left middle and lower lobes	3+	+ (S)	+ (S, S)	+
P40	48	M	cough, weight loss, loss of appetite, lassitude, lung apices have diffuse fibro cavitory changes and areas of reticular opacities on CT scan	3+	+ (S)	+ (S, S)	+
P41	55	M	cough, evening rise of temperature, weight loss, chills, fatigue, complete destruction of	3+	+ (S)	+ (S, S)	+

			left lung, non-homogenous opacities in the right lung				
P42	44	M	persistent cough, severe weight loss, night sweats cavitation in right upper lobe, nodular densities in right middle and lower lobes	1+	+ (S)	+ (S, S)	+
P43	60	F	cough, fever, weight loss, loss of appetite, lassitude, multiple nodular densities in the lung, left pleural effusion	3+	+ (S)	+ (S,R)	+
P44	39	M	cough, evening rise of temperature, weight loss, loss of appetite, hemoptysis, lassitude, non-homogenous opacities in the lung	2+	+ (S)	+ (S, S)	+
P45	27	M	cough, weight loss, loss of appetite, lassitude, multiple cavitory lesions in the right lung	3+	+ (S)	+ (S, S)	+
P46	34	M	cough, intermittent fever, weight loss, loss of appetite, body pain, night sweats, giddiness, lassitude, nodular densities in both the lungs	3+	+ (S)	+ (S, S)	+
P47	32	F	cough, fever, weight loss, loss of appetite, night sweats, left pleural effusion	3+	+ (S)	+ (S, S)	+

P48	50	M	cough, fever, chills, chest pain, joint pain, loss of appetite, cavitation in right lower lobe	3+	+ (S)	+ (S, S)	+
P49	39	M	cough, fever, weight loss, chest pain, night sweats, bilateral cavitation in upper lobes, right pleural effusion	3+	+ (S)	+ (S, S)	+
P50	50	M	cough, fever, weight loss, loss of appetite, lassitude, complete destruction of left lung, left pleural effusion	1+	+ (S)	+ (S, S)	+
P51	56	M	cough, evening rise of temperature, weight loss, night sweats, fatigue, body pain, bilateral cavitory lesion in upper lobes	3+	+ (S)	+ (S, S)	+
P52	41	M	cough, evening rise of temperature, weight loss, loss of appetite, hemoptysis, nodular densities in left middle and lower lobes, complete destruction of right lung	2+	+ (S)	+ (S, S)	+
P53	31	F	cough, fever, weight loss, loss of appetite, lassitude	2+	+ (S)	+ (S, S)	+
P54	49	F	cough, fever, weight loss, loss of appetite, multiple cavitory lesions in the left lung	3+	+ (S)	+ (S, S)	+
P55	50	M	cough, fever, chest pain, night sweats, cavitation in left upper lobe	3+	+ (S)	+ (S, S)	+

P56	48	M	cough, intermittent fever, weight loss, night sweats, lassitude, chest pain, multiple cavitary lesions in the left lung	2+	+	(S)	+	(S, S)	+
-----	----	---	---	----	---	-----	---	--------	---

FL-LPA First line - Line probe assay **Rif** Rifampicin susceptibility

SL-LPA First line - Line probe assay **Inh** Isoniazid susceptibility

CT scan Computed tomography scan **FQ** Fluoroquinolones susceptibility

AFB acid fast bacilli **K** Kanamycin susceptibility

.. Test not done/Data not available + Positive — Negative

(S) Sensitive (R) Resistant

Table E3: Clinical description of extrapulmonary tuberculosis patients included in the study.

ID	Age	Sex	Symptoms	Tests/Result	Final Diagnosis
Exploratory cohort					
EP1	33	M	swelling in the right posterior part of the neck	<i>FNAC</i> (right posterior cervical lymph node aspirate): Cytological features are suggestive of granulomatous lymphadenitis of tuberculous etiology. <i>ZN stain for AFB</i> : positive.	Lymph Node Tuberculosis
EP2	34	M	intermittent fever, burning micturition, abdominal pain, weight loss	<i>CT scan</i> (KUB region): Left sided polynephritis and ureteritis with multiple left ureteric strictures and moderate left hydronephrosis. Right lower ureter wall thickening suggesting of ureteritis with no ureteric narrowing or hydronephrosis. Small capacity urinary bladder with irregular thickening of bladder wall. Multiple enlarged para-aortic lymph node. Pleural thickening/effusion on right side. <i>Xpert-MTB/RIF</i> (urine): MTB detected; Rif sensitivity: indeterminate.	Tuberculous ureteritis

EP5	44	M	headache, intermittent fever, weight loss	MRI (brain): 4x4mm small ring enhancing lesion surrounding parenchymal edema on parietal corona radiata region, probably of Koch's. <i>Xpert-MTB/RIF</i> (CSF) - MTB detected; Rif sensitive.	TB meningitis
EP6	37	M	fever, weight loss, lassitude, swelling, pain and tenderness in left side of the neck	<i>FNAC</i> (left cervical lymph node aspirate): Cytological features are suggestive of reactive lymphadenitis of tuberculous etiology. <i>ZN stain for AFB</i> : negative. <i>FNAB</i> (left cervical lymph node biopsy): Histopathological features are suggestive of caseating granulomatous lymphadenitis of tuberculous etiology. <i>ZN stain for AFB</i> : positive.	Lymph Node Tuberculosis
EP7	64	M	evening rise of temperature, lassitude, loss of appetite, weight loss, pleural	Seronegative. <i>Biochemistry</i> (pleural fluid): ADA - 91U/ml. <i>Cytology</i> (pleural fluid): 98% lymphocytes.	Tuberculous pleural effusion

			effusion in right lung		
EP8	21	F	swelling and pain in the right anterior side of the neck	<p><i>FNAC</i> (right anterior cervical lymph node aspirate): Cytological features are suggestive of granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i>: positive.</p> <p><i>FNAB</i> (right anterior cervical lymph node biopsy): Histopathological features are suggestive of caseating granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i>: positive.</p>	Lymph Node Tuberculosis
EP9	35	M	evening rise of temperature, lassitude, weight loss, pleural effusion in left lung	<p><i>Sputum AFB</i>: negative.</p> <p><i>Xpert-MTB/RIF</i> (pleural fluid): MTB detected; Rif sensitive.</p>	Tuberculous pleural effusion

EP10	22	F	fever, abdominal pain, loss of appetite, irregular menstrual cycle	<i>USG</i> (abdomen): Cystic mass in the left adnexa. <i>FNAB</i> (tubo-ovarian mass): Histopathological features suggestive of caseating granulomatous lesion of tuberculous etiology. <i>ZN stain for AFB</i> : positive.	Ovarian Tuberculosis
EP11	31	F	swelling in right anterior side of the neck	<i>FNAC</i> (right anterior cervical lymph node aspirate): Cytological features are suggestive of caseating necrotising granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative.	Lymph Node Tuberculosis
EP12	37	M	abdominal pain, loose stools, vomiting, weight loss, evening rise of temperature, lassitude, giddiness	<i>CECT</i> (abdomen) - Diffuse wall thickening at terminal ileum, ileocecal junction, caecum and ascending colon. Adenopathy in adjacent mesenteric lymph nodes. Features suggestive of tuberculosis. <i>Chest Xray</i> : normal. <i>Xpert-MTB/RIF</i> (ileocecal mass): MTB detected; Rif sensitive.	Ileocecal tuberculosis

EP13	57	F	fever, headache, blurred vision, chronic uveitis	<i>IGRA</i> : positive. <i>Xpert-MTB/RIF</i> (aqueous humour): MTB detected; Rif sensitive.	Ocular tuberculosis
EP14	45	F	swelling in midline neck region - anterior part	<i>CECT</i> (neck) - Multiple inflamed lymph nodes in the media sternum region <i>FNAC</i> (pus from lymph nodes): Cytological features suggestive of necrotising lesion of tuberculous etiology. <i>ZN stain for AFB</i> : negative. <i>Xpert-MTB/RIF</i> (pus from anterior neck region): MTB detected; Rif sensitive.	Lymph Node Tuberculosis
EP15	38	F	cough, fever, weight loss, swelling and pain at the base of the neck	<i>Chest Xray</i> : normal. <i>Xpert-MTB/RIF</i> (sputum): MTB not detected. <i>FNAC</i> (left supraclavicular lymph node aspirate): Cytological features are suggestive of granulomatous lymphadenitis of tuberculous etiology. <i>ZN stain for AFB</i> : positive.	Lymph Node Tuberculosis

Validation cohort					
EP16	44	F	mild fever, night sweats, swelling in right anterior part of the neck	<i>FNAC</i> (right anterior cervical lymph node aspirate): Cytological features are suggestive of caseating granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : positive.	Lymph node tuberculosis
EP17	48	F	loss of appetite, night sweats, throat pain, cough, swelling in the right posterior part of the neck	<i>FNAC</i> (right posterior cervical lymph node aspirate): Cytological features are suggestive of granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative. <i>FNAB</i> (right posterior cervical lymph node biopsy): Histopathological features suggestive of granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative.	Lymph node tuberculosis
EP18	29	F	evening rise of temperature, night sweats, weight	<i>FNAC</i> (right posterior cervical lymph node aspirate): Cytological features are suggestive of caseating granulomatous lymphadenitis of	Lymph node tuberculosis

			loss, swelling in the right posterior part of the neck	tuberculous etiology. <i>ZN stain for AFB</i> : negative. <i>Xpert-MTB/RIF</i> (lymph node aspirate): MTB detected; Rif sensitive.	
EP19	36	M	pain and swelling in the right side of the neck	<i>FNAC</i> (right cervical lymph node aspirate): Cytological features are suggestive of caseating granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative.	Lymph node tuberculosis
EP20	41	M	cough, fever, headache, difficulty in breathing, abdominal pain, vomiting	<i>Sputum AFB</i> : negative. <i>Cytology</i> (pleural fluid): 98% lymphocytes. <i>Xpert-MTB/RIF</i> (pleural fluid): MTB detected; Rif sensitive.	Tuberculous Pleural Effusion
EP21	27	F	fever, weight loss, loss of appetite,	<i>Chest Xray</i> : left pleural effusion. <i>Xpert-MTB/RIF</i> (pleural fluid): MTB not detected.	Lymph node tuberculosis

			swelling, pain and tenderness in the left posterior part of the neck	<i>FNAC</i> (left cervical posterior lymph node aspirate): Cytological features are suggestive of caseating granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : positive.	
EP22	38	M	swelling, pain and tenderness in the midline neck region	<i>FNAC</i> (lymph node aspirate): Cytological features are suggestive of caseating tuberculous lesion. <i>ZN stain for AFB</i> : positive.	Lymph node tuberculosis
EP23	47	M	cough, fever, difficulty in breathing	Seronegative. <i>Chest Xray</i> : right pleural effusion. <i>Biochemistry</i> (pleural fluid): ADA - 91U/ml. <i>Cytology</i> (pleural fluid): 98% lymphocytes.	Tuberculous Pleural Effusion
EP24	32	F	pain and swelling in the left anterior side of the neck	<i>FNAC</i> (left cervical lymph node aspirate): Cytological features are suggestive of caseating granulomatous lesion of tuberculous etiology. <i>ZN stain for AFB</i> : positive.	Lymph node tuberculosis

EP25	30	F	fever, chills, abdominal pain, weight loss, weakness	<i>CT scan</i> (abdomen): Moderate ascites in peritoneal cavity possibly due to Koch's. <i>Biochemistry</i> (ascites fluid): ADA - 64·3U/ml. <i>Cytology</i> (ascites fluid): 98% lymphocytes. <i>Xpert-MTB/RIF</i> (ascites fluid): MTB detected; Rif sensitive.	Abdominal tuberculosis
EP26	20	F	pain and swelling in the right side of the neck	<i>FNAC</i> (right axillary lymph nodes aspirate): Cytological features are suggestive of caseating tuberculous lymphadenitis. <i>ZN stain for AFB</i> : positive.	Lymph node tuberculosis
EP27	30	M	pain and swelling in the right side of the jaw	<i>FNAC</i> (submandibular lymph node aspirate): Cytological features are suggestive of granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative. <i>Xpert-MTB/RIF</i> (lymph node aspirate): MTB not detected.	Lymph node tuberculosis
EP28	21	M	severe pain, tenderness,	<i>USG</i> (Neck): Significant Lymphadenopathy Present In The Left Side Of The Neck.	Lymph node tuberculosis

			swelling in the left side of the neck	<i>FNAC</i> (Left Cervical Lymph Node): Cytological Features Are Suggestive Of Caseating Tuberculous Lymphadenitis. <i>ZN Stain For AFB</i> : Positive.	
EP29	27	F	swelling and pain in the right supraclavicular region, evening rise of temperature, headache, lassitude	<i>USG</i> (neck): Matted lymphadenopathy (supraclavicular lymph nodes) of granulomatous etiology. <i>FNAC</i> (right supraclavicular lymph node): cytological features are suggestive of granulomatous lesion of tuberculous etiology. <i>ZN stain for AFB</i> : positive	Lymph node tuberculosis
EP30	34	F	cough, fever, loss of appetite, vomiting, lassitude, swelling	<i>FNAC</i> (supraclavicular lymph node aspirate): cytological features are suggestive of granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative	Lymph node tuberculosis

			in the right supraclavicular region	<i>Xpert-MTB/RIF</i> (supraclavicular lymph node aspirate): MTB detected; Rif sensitive	
EP31	50	M	cough, fever, weight loss, pain in lower abdomen, burning micturition	<i>Chest Xray</i> : normal. <i>Sputum AFB</i> : negative. <i>CT scan</i> (KUB): Thickened ureteral wall and calyx with no evidence of hydronephrosis, decreased bladder capacity. <i>Xpert-MTB/RIF</i> (urine): MTB detected; Rif sensitive.	Bladder tuberculosis
EP32	25	F	pain and swelling in the left anterior side of the neck, weight loss	<i>USG</i> (neck): Multiple inflamed lymph nodes favouring tuberculosis <i>FNAC</i> (left cervical lymph node): Cytological features are suggestive of granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative.	Lymph node tuberculosis
EP33	49	M	fever accompanied with	<i>Chest Xray</i> : left pleural effusion. <i>Xpert-MTB/RIF</i> (pleural fluid): MTB not detected.	Tuberculous Pleural Effusion

			chills late in the evening, weight loss, night sweats, chest pain, difficulty in breathing	<i>Biochemistry</i> (pleural fluid): ADA - 85U/ml. <i>Cytology</i> (pleural fluid): 98% lymphocytes.	
EP34	18	F	evening rise of temperature, swelling and pain in the right anterior part of the neck	<i>FNAC</i> (right cervical lymph node): Cytological features are suggestive of granulomatous lymphadenitis of Koch's etiology. <i>ZN stain for AFB</i> : negative.	Lymph node tuberculosis
EP35	31	M	severe pain, tenderness,	<i>CT scan</i> (chest): Multiple inflamed lymph nodes on the left anterior chest wall favouring tuberculosis.	Lymph node tuberculosis

			swelling in the left anterior chest wall	<i>FNAC</i> (right humeral lymph node): Cytological features are suggestive of granulomatous lesion of Koch's etiology. <i>ZN stain for AFB</i> : positive.	
--	--	--	---	---	--

CECT scan Contrast Enhanced CT scan

FNAC Fine needle aspirate cytology

MRI Magnetic Resonance Imaging

FNAB Fine needle aspirate biopsy

USG Ultrasound scan

ADA Adenosine deaminase

IGRA Interferon- γ release assay

ZN Ziehl-Neelson

Table E4: Clinical description of sick controls in the study.

ID	Age	Sex	Symptoms	AFB	PCR	Culture
SC1	38	M	fever, chills, cough, night sweats, vomiting, non-homogenous opacities in the lungs	—	..	—
SC2	32	F	fever, cough, night sweats, malaise, lassitude, pain in the left side of the chest, nodular granules in the right lung, pleural effusion in the left lung	—	..	—
SC3	45	M	productive cough, fever, Xray suggestive of acute bronchitis	—	..	—
SC4	40	F	persistent cough, fever, loss of appetite, body pain, headache, pulmonary infiltrates in the left lung	—	..	—
SC5	39	M	cough, fever, chest pain, right pleural effusion	—	..	—
SC6	47	M	cough, evening rise of temperature, loss of appetite	—	..	—
SC7	44	F	cough, intermittent fever, breathlessness, difficulty in breathing, complete destruction of right lung	—	..	—
SC8	50	M	persistent cough, fever, malaise, lassitude, cavitation in left upper lobe	—	..	—
SC9	49	F	cough, fever, weight loss, lassitude	—	..	—
SC10	44	M	cough, fever, nodules in the right lung	—	..	—
SC11	51	M	productive cough, chest pain, breathlessness, Xray suggestive of bronchial asthma and COPD	—	..	—

SC12	43	F	cough, fever, congestion, loss of appetite	—	..	—
SC13	47	M	cough, fever, chest pain, weight loss, night sweats, weakness, left pleural effusion, cavitary lesions and nodules in the right lung	—	—	—
SC14	51	M	cough, chest pain, Xray suggestive of acute infective exacerbation of COPD	—	—	—
SC15	23	F	cough, fever, night sweats, left pleural effusion	—	..	—
SC16	37	F	cough, fever, loss of appetite	—	..	—
SC17	39	M	cough, fever, chest pain, bilateral cavitary lesions in upper and middle lobes	—	—	—
SC18	36	M	cough, fever, weight loss, congestion, breathing difficulty, consistent non-homogenous opacities in the lungs	—	..	—
SC19	30	M	cough, hemoptysis, evening rise of temperature, chest pain, left pleural effusion, non- homogenous opacities in the lungs	—	..	—
SC20	35	M	cough, fever, weight loss, chest pain, left pleural effusion	—	—	—
SC21	58	F	persistent cough	—	..	—
SC22	60	F	persistent cough, fever, right pleural effusion, multiple cavitary lesions in the left lung	—	—	—

SC23	57	M	cough, fever, chest pain, nodular densities in the lung	—	..	—
SC24	40	F	evening rise of temperature accompanied with chills, cough, pulmonary infiltrates in the left lung	—	..	—
SC25	45	M	cough, weight loss, hemoptysis, chills, non-homogenous opacities in the lungs	—	—	—
SC26	68	M	productive cough, weight loss, lassitude, cavitary lesion in right middle and lower lobes	—	..	—
SC27	39	M	cough, intermittent fever, chest pain	—	..	—
SC28	51	M	severe chest pain, fever, cough, left pleural effusion	—	—	—
SC29	26	M	cough, throat pain, loss of appetite, cavitation in right upper and middle lobes	—	..	—
SC30	55	M	productive cough, chest pain, lassitude, cavitation in left upper lobe	—	—	—
SC31	46	F	cough, fever, weight loss, loss of appetite, non-homogenous opacities in the lungs	—	—	—
SC32	53	F	cough, fever, night sweats	—	..	—
SC33	51	M	cough, fever, weight loss, loss of appetite, chest pain, pleural effusion in both the lungs	—	..	—

.. Test was not performed

Table E5. Summary of the antibody panels used in the study.

	Marker	Clone	Fluorophore	Manufacturer
EXPLORATORY COHORT	IP-10	6D4/D6/G2	PE	BD Biosciences
	CD38	LS198-4-3	PC5.5	Beckman
	CD27	1A4CD27	PC7	Coulter
	IL-10	JES3-19F1	APC	BD Biosciences
	CD19	HIB19	AF700	
	CD4	RPA-T4	APC-Cy7	
	Live/Dead	-	FVS450	
	CD3	UCHT1	BV650	
	TNF- α	MAb11	BV750	
VALIDATION COHORT	IFN γ	45.15	FITC	Beckman Coulter
	CD4	13B8.2	PE	
	CD3	UCHT1	ECD	
	CD38	LS198-4-3	PC5.5	
	CD27	1A4CD27	PC7	
	IL-2	MQ1- 17H12	APC	BD Biosciences
	Live/Dead	-	FVS450	
	TNF- α	MAb11	BV750	

Table E6. Biomarker performance of CD38⁺CD27⁻ and CD38⁺ within mono- and polyfunctional CD4⁺ T cells.

Diagnostic potentials of several biomarkers with AUC values > 0.875 in *Mtb*-CW stimulated whole blood have been summarised. Number of samples with significant responses for each cytokine or their combination have been listed. For AND combinations, response was considered significant if all the cytokines involved in the combination were independently significant. For OR combinations, criteria for significant responses were same as that for TNF- α . To counter the problem of insignificant cytokine responses in whole blood, OR combinations were evaluated to check if antibodies for 2 or more cytokines could be used in the same detector channel. Mann Whitney *U* test for used to compare the TB (PTB and EPTB) and non-TB (LTBI, HC and SC) groups. AUC: area under the curve.

Phenotype		CD38 ⁺ CD27 ⁻																				CD38 ⁺												
Functional Profile		TNF- α ⁺	IL-2 ⁺	IFN- γ ⁺	IFN- γ ⁺ IL-2 ⁺	IFN- γ ⁺ TNF- α ⁺	IL-2 ⁺ TNF- α ⁺	IFN- γ ⁺ IL-2 ⁺ TNF- α ⁺	IFN- γ ⁺ OR IL-2 ⁺	IFN- γ ⁺ OR TNF- α ⁺	IL-2 ⁺ OR TNF- α ⁺	IFN- γ ⁺ OR IL-2 ⁺ OR TNF- α ⁺	IFN- γ ⁺	IFN- γ ⁺ IL-2 ⁺	IFN- γ ⁺ TNF- α ⁺	IL-2 ⁺ TNF- α ⁺	IFN- γ ⁺ IL-2 ⁺ TNF- α ⁺																	
Cut off		> 7.89	> 6.50	> 11.49	> 8.91	> 12.03	> 7.57	> 8.91	> 8.90	> 8.33	> 8.13	> 8.56	> 27.28	> 17.80	> 22.41	> 18.29	> 16.91																	
Samples with significant cytokine response																																		
		R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	R	NR	
TB	PTB	38	3	30	11	32	9	27	14	32	9	29	12	27	14	33	8	38	3	38	3	40	1	32	9	27	14	32	9	29	12	27	14	
	EPTB	19	1	17	3	17	3	17	3	17	3	17	3	17	3	17	3	19	1	19	1	18	2	17	3	17	3	17	3	17	3	17	3	
Non TB	LTBI	32	0	27	5	29	3	25	7	29	3	27	5	25	7	29	3	32	0	32	0	32	0	29	3	25	7	29	3	27	5	25	7	
	HC	34	5	29	10	27	12	25	14	26	13	28	11	24	15	29	10	34	5	31	8	33	6	27	12	25	14	26	13	28	11	24	15	
	SC	28	5	23	10	25	8	19	14	23	10	22	11	18	15	26	7	29	4	29	4	28	5	25	8	19	14	23	10	22	11	18	15	
AUC		0.9296		0.8874		0.9322		0.9032		0.9254		0.8902		0.8994		0.9274		0.9278		0.9183		0.9206		0.9276		0.8785		0.941		0.8855		0.8782		
P-value		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001				
Sensitivity(%)		94.74		85.11		95.92		90.91		95.92		91.3		90.91		90		92.98		89.47		87.93		85.71		84.09		91.84		84.78		84.09		
Specificity(%)		86.17		87.34		87.65		86.96		85.9		87.01		86.57		88.1		86.32		86.96		88.17		86.42		89.86		87.18		88.39		88.06		
Accuracy(%)		89.41		86.51		90.77		88.5		89.77		88.61		88.29		88.81		88.82		87.92		88.08		86.15		87.61		88.98		87.04		86.49		
All tested samples (PTB – 41; EPTB – 20; LTBI – 32; HC – 39; SC – 33) (Samples with insignificant cytokine response were considered negative for the respective biomarker and their values were normalised to zero)																																		
AUC		0.8805		0.7406		0.7912		0.7431		0.7883		0.7481		0.7422		0.7952		0.879		0.8719		0.8874		0.7807		0.7126		0.7942		0.7273		0.7138		
P-value		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001		< 0.0001				
Sensitivity(%)		88.52		65.57		77.05		65.57		77.05		68.85		65.57		73.77		86.89		83.61		83.61		68.85		60.66		73.77		63.93		60.66		
Specificity(%)		87.5		90.38		90.38		91.35		89.42		90.38		91.35		90.38		87.5		88.46		89.42		89.42		93.27		90.38		91.35		92.31		
Accuracy(%)		87.88		81.21		85.45		81.82		84.85		82.42		81.82		84.24		87.27		86.67		87.27		81.82		81.21		84.24		81.21		80.61		

REFERENCES

- E1. Hirschfield GR, McNeil M, Brennan PJ. Peptidoglycan-associated polypeptides of *Mycobacterium tuberculosis*. *J. Bacteriol* 1990; 172:1005–13.
- E2. Rabodoarivelo MS, Aerts M, Vandamme P, Palomino JC, Rasolofo V, Martin A. Optimizing of a protein extraction method for *Mycobacterium tuberculosis* proteome analysis using mass spectrometry. *J Microbiol Methods* 2016; 131:144–47.